Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 22;13(1):20521.
doi: 10.1038/s41598-023-47407-y.

Platform for the interdisciplinary study of cardiovascular, metabolic and neurovascular diseases (PICMAN) protocol

Mayank Dalakoti  1   2   3 , Melvin Khee Shing Leow  4   5 , Chin Meng Khoo  6   4 , Hayang Yang  7 , Lieng Hsi Ling  8   4 , Mark Muthiah  6   4 , Eunice Tan  6 , Jonathan Lee  6   4 , Yock Young Dan  6   4 , Nicholas Chew  8   7 , Wei Qiang Seow  4   7 , Poh Loong Soong  4   7 , Louis Gan  4   7 , Rijan Gurung  4   7 , Matthew Ackers-Johnson  4   7 , Han Wei Hou  5 , Karishma Sachaphibulkij  9 , Paul MacAry  9 , Gwen Low  4   7 , Christy Ang  4   7 , Tee Joo Yeo  8   4 , Andie Hartanto Djohan  8   10 , Tony Li  8 , Wesley Yeung  8 , Rodney Soh  8 , Ching Hui Sia  8   4   7 , Vinay Panday  8 , Shaun S E Loong  4   7 , Benjamin Y Q Tan  6   4 , Leonard L L Yeo  6   4 , Lynette Teo  11 , Pierce Chow  12 , Roger Foo  8   4   7
Affiliations

Platform for the interdisciplinary study of cardiovascular, metabolic and neurovascular diseases (PICMAN) protocol

Mayank Dalakoti et al. Sci Rep. .

Abstract

Through extensive multisystem phenotyping, the central aim of Project PICMAN is to correlate metabolic flexibility to measures of cardiometabolic health, including myocardial diastolic dysfunction, coronary and cerebral atherosclerosis, body fat distribution and severity of non-alcoholic fatty liver disease. This cohort will form the basis of larger interventional trials targeting metabolic inflexibility in the prevention of cardiovascular disease. Participants aged 21-72 years with no prior manifest atherosclerotic cardiovascular disease (ASCVD) are being recruited from a preventive cardiology clinic and an existing cohort of non-alcoholic fatty liver disease (NAFLD) in an academic medical centre. A total of 120 patients will be recruited in the pilot phase of this study and followed up for 5 years. Those with 10-year ASCVD risk ≥ 5% as per the QRISK3 calculator are eligible. Those with established diabetes mellitus are excluded. Participants recruited undergo a detailed assessment of health behaviours and physical measurements. Participants also undergo a series of multimodality clinical phenotyping comprising cardiac tests, vascular assessments, metabolic tests, liver and neurovascular testing. Blood samples are also being collected and banked for plasma biomarkers, 'multi-omics analyses' and for generation of induced pluripotent stem cells (iPSC). Extensive evidence points to metabolic dysregulation as an early precursor of cardiovascular disease, particularly in Asia. We hypothesise that quantifiable metabolic inflexibility may be representative of an individual in his/her silent, but high-risk progression towards insulin resistance, diabetes and cardiovascular disease. The platform for interdisciplinary cardiovascular-metabolic-neurovascular diseases (PICMAN) is a pilot, prospective, multi-ethnic cohort study.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
(Upper panel) Assessments and phenotyping performed; (lower panel) Timepoints of assessments and phenotyping.
See this image and copyright information in PMC

References

    1. Phan TP, et al. Forecasting the burden of type 2 diabetes in Singapore using a demographic epidemiological model of Singapore. BMJ Open Diabetes Res. Care. 2014;2:e000012. doi: 10.1136/bmjdrc-2013-000012. - DOI - PMC - PubMed
    1. Estes C, et al. Modelling NAFLD disease burden in four Asian regions-2019-2030. Aliment. Pharmacol. Ther. 2020;51:801–811. doi: 10.1111/apt.15673. - DOI - PMC - PubMed
    1. Younossi ZM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology. 2023;77:1335–1347. doi: 10.1097/HEP.0000000000000004. - DOI - PMC - PubMed
    1. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–133. doi: 10.1002/hep.29466. - DOI - PMC - PubMed
    1. Stefan N, Schick F, Birkenfeld AL, Häring HU, White MF. The role of hepatokines in NAFLD. Cell Metab. 2023;35:236–252. doi: 10.1016/j.cmet.2023.01.006. - DOI - PMC - PubMed